Search results (197)
« Back to NewsIcosphere Biosciences appoints Dr John Beadle as Non-Executive Director
27 November 2025
Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.
U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health
21 November 2025
U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.
Abbott to acquire Exact Sciences
20 November 2025
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.
Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease
19 November 2025
Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK
18 November 2025
Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.
Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation
18 November 2025
Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.
PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule
12 November 2025
The Composition of Matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.
Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
6 November 2025
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.
Enara Bio’s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies
4 November 2025
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX™ as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery
31 October 2025
The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025
27 October 2025
U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
MediMabBio secures KRW 25.6B in Series B funding to advance pipeline and global partnerships
23 October 2025
MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
Exogene Graduates from the BioEscalator
15 October 2025
We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.
Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO
14 October 2025
Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.
MediMabBio Wins 1st Place at Japan’s “Innovation Tiger 2025”
12 October 2025
MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
Dr.Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)
10 October 2025
Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.
Professor Heidi Johansen-Berg joins the BioEscalator Management Board
8 October 2025
We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer
6 October 2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
23 September 2025
53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
PepGen Announces Pricing of $100M Public Offering
23 September 2025
PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.